Ronald Gilman, MD
Pulmonary Disease · Riverside, RINPI 1346237039
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.5% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 82.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $112 and has fallen 88.4% since, to $13 in 2022. That places this record below the midpoint for pulmonary disease clinicians in RI, where the typical reported total is $245.
Across 3 payments — averaging $45.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$112
- AstraZeneca$25
Across 28 payments — averaging $12,578 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$127K
- Cipla USA Inc.$126K
- Hikma Pharmaceuticals USA$99K
What the payments were for
- Food & beverage$12592%
- Education$128%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 1 | $112 |
| AstraZeneca | 2 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$112
How this compares
$136 in reported general payments places this provider in the 45th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $81,017 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $32,692 |
| EliquisApixaban | 27 | $31,448 |
| OzempicSemaglutide | 18 | $21,052 |
| XareltoRivaroxaban | 11 | $15,031 |
| TrulicityDulaglutide | 12 | $13,400 |
| Spiriva HandihalerTiotropium Bromide | 15 | $12,410 |
| Spiriva RespimatTiotropium Bromide | 17 | $11,543 |
| JardianceEmpagliflozin | 12 | $11,402 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $11,129 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $10,619 |
| Arnuity ElliptaFluticasone Furoate | 41 | $10,130 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,127 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $7,646 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $112 | $134,458245 claims |
| AstraZenecaSymbicort | $25 | $8,12725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 59 pulmonary disease providers in Rhode Island.
Other pulmonary disease in Riverside
- Corey VentetuoloRiverside$51K
- John LadettoRiverside$39K
- Douglas MartinRiverside$4K
- James KlingerRiverside$3K
- Matthew BallenbergerRiverside$1K
- Peter KarczmarRiverside$245
- James MyersRiverside$136
- Seema AminRiverside$110
- Michael BlundinRiverside$100
- E Jane CarterRiverside$75
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.